{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T05:49:07Z","timestamp":1778219347986,"version":"3.51.4"},"reference-count":194,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,9,27]],"date-time":"2016-09-27T00:00:00Z","timestamp":1474934400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Seraj Kaki Chair"},{"DOI":"10.13039\/501100004054","name":"King Abdulaziz University, Jeddah, Saudi Arabia","doi-asserted-by":"crossref","award":["MBK\/03\/434"],"award-info":[{"award-number":["MBK\/03\/434"]}],"id":[{"id":"10.13039\/501100004054","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","internationaljournalofcardiology.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.ijcard.2016.09.081","type":"journal-article","created":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T08:42:04Z","timestamp":1475311324000},"page":"268-283","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Consensus clinical recommendations for the management of plasma lipid disorders in the Middle East"],"prefix":"10.1016","volume":"225","author":[{"given":"Nasreen","family":"Al Sayed","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khalid","family":"Al Waili","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatheya","family":"Alawadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saeed","family":"Al-Ghamdi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wael","family":"Al Mahmeed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fahad","family":"Al-Nouri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mona","family":"Al Rukhaimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khalid","family":"Al-Rasadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zuhier","family":"Awan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Farghaly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Hassanein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hani","family":"Sabbour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Zubaid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip","family":"Barter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.ijcard.2016.09.081_bb0005","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s11745-010-3408-1","article-title":"Atherogenic dyslipidemia: cardiovascular risk and dietary intervention","volume":"45","author":"Musunuru","year":"2010","journal-title":"Lipids"},{"issue":"6 Suppl.","key":"10.1016\/j.ijcard.2016.09.081_bb0010","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jacl.2015.09.002","article-title":"National Lipid Association recommendations for patient-centered management of dyslipidemia: part 2","volume":"9","author":"Jacobson","year":"2015","journal-title":"J. Clin. Lipidol."},{"issue":"25 Suppl.","key":"10.1016\/j.ijcard.2016.09.081_bb0015","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jacc.2012.11.002","article-title":"The worldwide environment of cardiovascular disease: prevalence, diagnosis, therapy, and policy issues: a report from the American College of Cardiology","volume":"60","author":"Laslett","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"issue":"14","key":"10.1016\/j.ijcard.2016.09.081_bb0020","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/eurheartj\/ehr158","article-title":"ESC\/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)","volume":"32","author":"Reiner","year":"2011","journal-title":"Eur. Heart J."},{"issue":"25 Pt B","key":"10.1016\/j.ijcard.2016.09.081_bb0025","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"63","author":"Stone","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"issue":"6","key":"10.1016\/j.ijcard.2016.09.081_bb0030","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.amjcard.2012.04.062","article-title":"Secondary causes of dyslipidemia","volume":"110","author":"Vodnala","year":"2012","journal-title":"Am. J. Cardiol."},{"issue":"6","key":"10.1016\/j.ijcard.2016.09.081_bb0035","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.jacl.2009.10.001","article-title":"Acquired severe hypercholesterolemia and hypoalphalipoproteinemia","volume":"3","author":"Awan","year":"2009","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.ijcard.2016.09.081_bb0040","author":"World Health Organization"},{"key":"10.1016\/j.ijcard.2016.09.081_bb0045","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.atherosclerosis.2016.07.925","article-title":"Dyslipidaemia in the Middle East: Current status and call to action","volume":"252","author":"Al-Rasadi","year":"2016","journal-title":"Atherosclerosis"},{"issue":"7","key":"10.1016\/j.ijcard.2016.09.081_bb0050","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1258\/shorts.2011.011019","article-title":"Prevalences of overweight, obesity, hyperglycaemia, hypertension and dyslipidaemia in the Gulf: systematic review","volume":"2","author":"Alhyas","year":"2011","journal-title":"JRSM Short Rep."},{"key":"10.1016\/j.ijcard.2016.09.081_bb0055","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/235101","article-title":"Prevalence of cardiovascular disease and associated risk factors among adult population in the Gulf region: a systematic review","author":"Aljefree","year":"2015","journal-title":"Adv. Public Health"},{"issue":"1","key":"10.1016\/j.ijcard.2016.09.081_bb0060","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/clc.20873","article-title":"Prevalence and impact of cardiovascular risk factors among patients presenting with acute coronary syndrome in the middle East","volume":"34","author":"El-Menyar","year":"2011","journal-title":"Clin. Cardiol."},{"issue":"1","key":"10.1016\/j.ijcard.2016.09.081_bb0065","doi-asserted-by":"crossref","first-page":"9","DOI":"10.5144\/0256-4947.2012.9","article-title":"Baseline characteristics, management practices, and long-term outcomes of Middle Eastern patients in the Second Gulf Registry of Acute Coronary Events (Gulf RACE-2)","volume":"32","author":"Alhabib","year":"2012","journal-title":"Ann. Saudi Med."},{"issue":"11","key":"10.1016\/j.ijcard.2016.09.081_bb0070","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.annepidem.2014.08.001","article-title":"Hypercholesterolemia and its associated risk factors-Kingdom of Saudi Arabia, 2013","volume":"24","author":"Basulaiman","year":"2014","journal-title":"Ann. Epidemiol."},{"issue":"11 Suppl.","key":"10.1016\/j.ijcard.2016.09.081_bb0075","first-page":"247","article-title":"Diabetic dyslipidaemia in Kuwait","author":"Akanji","year":"2002","journal-title":"Med. Princ. Pract."},{"issue":"8","key":"10.1016\/j.ijcard.2016.09.081_bb0080","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0102830","article-title":"Cardiovascular risk factor burden in Africa and the Middle East: the Africa Middle East Cardiovascular Epidemiological (ACE) study","volume":"9","author":"Alsheikh-Ali","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.ijcard.2016.09.081_bb0085","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0084350","article-title":"Results of the Dyslipidemia International Study (DYSIS)-Middle East: clinical perspective on the prevalence and characteristics of lipid abnormalities in the setting of chronic statin treatment","volume":"9","author":"Al Sifri","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.ijcard.2016.09.081_bb0090","doi-asserted-by":"crossref","first-page":"67","DOI":"10.4103\/2230-8210.91193","article-title":"Metabolic syndrome in the Middle East","volume":"16","author":"Sliem","year":"2012","journal-title":"Ind. J. Endocrinol. Metab."},{"issue":"2","key":"10.1016\/j.ijcard.2016.09.081_bb0095","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.diabres.2013.11.008","article-title":"Diabetes in the Middle-East and North Africa: an update","volume":"103","author":"Majeed","year":"2014","journal-title":"Diabetes Res. Clin. Pract."},{"issue":"4","key":"10.1016\/j.ijcard.2016.09.081_bb0100","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1177\/2047487312465525","article-title":"Association of risk factors with acute myocardial infarction in Middle Eastern countries: the INTERHEART Middle East study","volume":"21","author":"Gehani","year":"2014","journal-title":"Eur. J. Prev. Cardiol."},{"issue":"6","key":"10.1016\/j.ijcard.2016.09.081_bb0105","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.jacl.2013.10.001","article-title":"An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia","volume":"7","author":"Grundy","year":"2013","journal-title":"J. Clin. Lipidol."},{"issue":"2","key":"10.1016\/j.ijcard.2016.09.081_bb0110","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jacl.2015.02.003","article-title":"National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1\u2014full report","volume":"9","author":"Jacobson","year":"2015","journal-title":"J. Clin. Lipidol."},{"issue":"3","key":"10.1016\/j.ijcard.2016.09.081_bb0115","first-page":"v-305","article-title":"KDIGO Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease","volume":"3","author":"KDIGO","year":"2013","journal-title":"Kidney Int. Suppl."},{"key":"10.1016\/j.ijcard.2016.09.081_bb0120","first-page":"11","article-title":"American Association of Clinical Endocrinologists' guidelines for management of dyslipidemia and prevention of atherosclerosis","volume":"18","author":"Jellinger","year":"2012","journal-title":"Endocr. Pract."},{"issue":"20","key":"10.1016\/j.ijcard.2016.09.081_bb0125","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1161\/CIRCULATIONAHA.108.804146","article-title":"Fasting and nonfasting lipid levels: influence of normal food intake on lipids, lipoproteins, apolipoproteins, and cardiovascular risk prediction","volume":"118","author":"Langsted","year":"2008","journal-title":"Circulation"},{"issue":"23","key":"10.1016\/j.ijcard.2016.09.081_bb0130","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","article-title":"Lipoprotein(a) as a cardiovascular risk factor: current status","volume":"31","author":"Nordestgaard","year":"2010","journal-title":"Eur. Heart J."},{"issue":"4","key":"10.1016\/j.ijcard.2016.09.081_bb0135","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jama.2009.1063","article-title":"Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality","volume":"302","author":"Erqou","year":"2009","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.ijcard.2016.09.081_bb0140","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1210\/jc.2011-3213","article-title":"Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline","volume":"97","author":"Berglund","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"6","key":"10.1016\/j.ijcard.2016.09.081_bb0145","doi-asserted-by":"crossref","first-page":"759","DOI":"10.2174\/1570161113666150827125040","article-title":"Identification and treatment of patients with homozygous familial hypercholesterolaemia: information and recommendations from a Middle East Advisory Panel","volume":"13","author":"Al-Ashwal","year":"2015","journal-title":"Curr. Vasc. Pharmacol."},{"issue":"2","key":"10.1016\/j.ijcard.2016.09.081_bb0150","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jacl.2014.11.008","article-title":"Familial hypercholesterolemia mutations in the Middle Eastern and North African region: a need for a national registry","volume":"9","author":"Bamimore","year":"2015","journal-title":"J. Clin. Lipidol."},{"issue":"24","key":"10.1016\/j.ijcard.2016.09.081_bb0155","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1093\/hmg\/11.24.3019","article-title":"Molecular mechanisms of autosomal recessive hypercholesterolemia","volume":"11","author":"Wilund","year":"2002","journal-title":"Hum. Mol. Genet."},{"issue":"2","key":"10.1016\/j.ijcard.2016.09.081_bb0160","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ymgme.2010.11.006","article-title":"Homozygous familial hypercholesterolemia in Lebanon: a genotype\/phenotype correlation","volume":"102","author":"Fahed","year":"2011","journal-title":"Mol. Genet. Metab."},{"issue":"4683","key":"10.1016\/j.ijcard.2016.09.081_bb0165","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1126\/science.3155573","article-title":"Mutation in LDL receptor: Alu-Alu recombination deletes exons encoding transmembrane and cytoplasmic domains","volume":"227","author":"Lehrman","year":"1985","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.ijcard.2016.09.081_bb0170","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ygeno.2015.12.001","article-title":"Identification of a recurrent frameshift mutation at the LDLR exon 14 (c.2027delG, p.(G676Afs*33)) causing familial hypercholesterolemia in Saudi Arab homozygous children","volume":"107","author":"Al-Allaf","year":"2016","journal-title":"Genomics"},{"issue":"1","key":"10.1016\/j.ijcard.2016.09.081_bb0175","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.gene.2015.03.064","article-title":"Next generation sequencing to identify novel genetic variants causative of autosomal dominant familial hypercholesterolemia associated with increased risk of coronary heart disease","volume":"565","author":"Al-Allaf","year":"2015","journal-title":"Gene"},{"key":"10.1016\/j.ijcard.2016.09.081_bb0180","doi-asserted-by":"crossref","first-page":"114021","DOI":"10.1038\/hgv.2014.21","article-title":"Identification of a novel nonsense variant c.1332dup, p.(D445*) in the LDLR gene that causes familial hypercholesterolemia","volume":"1","author":"Al-Allaf","year":"2014","journal-title":"Hum. Genome Var."},{"issue":"3","key":"10.1016\/j.ijcard.2016.09.081_bb0185","doi-asserted-by":"crossref","first-page":"559","DOI":"10.18388\/abp.2015_1015","article-title":"Screening for genetic mutations in LDLR gene with familial hypercholesterolemia patients in the Saudi population","volume":"62","author":"Alharbi","year":"2015","journal-title":"Acta Biochim. Pol."},{"issue":"5","key":"10.1016\/j.ijcard.2016.09.081_bb0190","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1159\/000484783","article-title":"A xanthomatosis-susceptibility gene may exist in a Syrian family with familial hypercholesterolemia","volume":"5","author":"Vergopoulos","year":"1997","journal-title":"Eur. J. Hum. Genet."},{"issue":"5","key":"10.1016\/j.ijcard.2016.09.081_bb0195","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s004390050263","article-title":"Molecular genetics of familial hypercholesterolemia in Israel","volume":"98","author":"Reshef","year":"1996","journal-title":"Hum. Genet."},{"key":"10.1016\/j.ijcard.2016.09.081_bb0200","author":"QRISK. QRISK\u00ae2"},{"issue":"1","key":"10.1016\/j.ijcard.2016.09.081_bb0205","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1136\/heartjnl-2013-304474","article-title":"Ethnicity and prediction of cardiovascular disease: performance of QRISK2 and Framingham scores in a U.K. tri-ethnic prospective cohort study (SABRE\u2014Southall And Brent REvisited)","volume":"100","author":"Tillin","year":"2014","journal-title":"Heart"},{"issue":"4","key":"10.1016\/j.ijcard.2016.09.081_bb0210","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1080\/13557858.2013.797568","article-title":"Ethnic group differences in cardiovascular risk assessment scores: national cross-sectional study","volume":"19","author":"Dalton","year":"2014","journal-title":"Ethn Health"},{"key":"10.1016\/j.ijcard.2016.09.081_bb0215","author":"European Society of Cardiology, SCORE Risk Charts"},{"issue":"6","key":"10.1016\/j.ijcard.2016.09.081_bb0220","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1001\/jama.297.6.611","article-title":"Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score","volume":"297","author":"Ridker","year":"2007","journal-title":"JAMA"},{"issue":"22","key":"10.1016\/j.ijcard.2016.09.081_bb0225","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1161\/CIRCULATIONAHA.108.814251","article-title":"C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men","volume":"118","author":"Ridker","year":"2008","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.ijcard.2016.09.081_bb0230","doi-asserted-by":"crossref","first-page":"266","DOI":"10.7326\/M14-1281","article-title":"An analysis of calibration and discrimination among multiple cardiovascular risk scores in a modern multiethnic cohort","volume":"162","author":"DeFilippis","year":"2015","journal-title":"Ann. Intern. Med."},{"issue":"14","key":"10.1016\/j.ijcard.2016.09.081_bb0235","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1161\/CIRCULATIONAHA.111.075929","article-title":"Comparison of the Framingham and Reynolds Risk scores for global cardiovascular risk prediction in the multiethnic Women's Health Initiative","volume":"125","author":"Cook","year":"2012","journal-title":"Circulation"},{"issue":"25 Pt B","key":"10.1016\/j.ijcard.2016.09.081_bb0240","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1016\/j.jacc.2013.11.005","article-title":"2013 ACC\/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"63","author":"Goff","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"issue":"6","key":"10.1016\/j.ijcard.2016.09.081_bb0245","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.107.699579","article-title":"General cardiovascular risk profile for use in primary care: the Framingham Heart Study","volume":"117","author":"D'Agostino","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2016.09.081_bb0250","author":"Framingham Heart Study"},{"issue":"5","key":"10.1016\/j.ijcard.2016.09.081_bb0255","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0126779","article-title":"The clinical performance of an office-based risk scoring system for fatal cardiovascular diseases in North-East of Iran","volume":"10","author":"Sepanlou","year":"2015","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.ijcard.2016.09.081_bb0260","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jacc.2007.03.037","article-title":"The Framingham predictive instrument in chronic kidney disease","volume":"50","author":"Weiner","year":"2007","journal-title":"J. Am. Coll. Cardiol."},{"issue":"6","key":"10.1016\/j.ijcard.2016.09.081_bb0265","first-page":"412","article-title":"Comparison of the Framingham risk and SCORE models in predicting the presence and severity of coronary artery disease considering SYNTAX score","volume":"16","author":"Gunaydin","year":"2016","journal-title":"Anatol. J. Cardiol."},{"issue":"3","key":"10.1016\/j.ijcard.2016.09.081_bb0270","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1093\/aje\/kws204","article-title":"Clinical usefulness of the Framingham cardiovascular risk profile beyond its statistical performance: the Tehran Lipid and Glucose Study","volume":"176","author":"Khalili","year":"2012","journal-title":"Am. J. Epidemiol."},{"issue":"6","key":"10.1016\/j.ijcard.2016.09.081_bb0275","doi-asserted-by":"crossref","first-page":"403","DOI":"10.5001\/omj.2015.81","article-title":"Dyslipidemia in the Arabian Gulf and its impact on cardiovascular risk outcome","volume":"30","author":"Al-Rasadi","year":"2015","journal-title":"Oman Med. J."},{"issue":"10","key":"10.1016\/j.ijcard.2016.09.081_bb0280","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1161\/hc3501.095214","article-title":"Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: the Atherosclerosis Risk in Communities (ARIC) Study","volume":"104","author":"Sharrett","year":"2001","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.ijcard.2016.09.081_bb0285","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/ncpcardio0555","article-title":"Are we lowering LDL cholesterol sufficiently?","volume":"3","author":"Barter","year":"2006","journal-title":"Nat. Clin. Pract. Cardiovasc. Med."},{"issue":"9493","key":"10.1016\/j.ijcard.2016.09.081_bb0290","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.ijcard.2016.09.081_bb0295","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nrd1112","article-title":"Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors","volume":"2","author":"Tobert","year":"2003","journal-title":"Nat. Rev. Drug Discov."},{"issue":"20","key":"10.1016\/j.ijcard.2016.09.081_bb0300","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1001\/jama.279.20.1615","article-title":"Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS\/TexCAPS. Air Force\/Texas Coronary Atherosclerosis Prevention Study","volume":"279","author":"Downs","year":"1998","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.ijcard.2016.09.081_bb0305","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.atherosclerosissup.2004.08.027","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)","volume":"5","author":"Pedersen","year":"2004","journal-title":"Atheroscler. Suppl."},{"issue":"9326","key":"10.1016\/j.ijcard.2016.09.081_bb0310","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial","volume":"360","year":"2002","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.ijcard.2016.09.081_bb0315","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJM199511163332001","article-title":"Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group","volume":"333","author":"Shepherd","year":"1995","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"10.1016\/j.ijcard.2016.09.081_bb0320","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJM199610033351401","article-title":"The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators","volume":"335","author":"Sacks","year":"1996","journal-title":"N. Engl. J. Med."},{"issue":"19","key":"10.1016\/j.ijcard.2016.09.081_bb0325","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199811053391902","volume":"339","year":"1998","journal-title":"N. Engl. J. Med."},{"issue":"24","key":"10.1016\/j.ijcard.2016.09.081_bb0330","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1001\/jama.287.24.3215","article-title":"Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial","volume":"287","author":"Serruys","year":"2002","journal-title":"JAMA"},{"issue":"9364","key":"10.1016\/j.ijcard.2016.09.081_bb0335","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(03)12948-0","volume":"361","author":"Sever","year":"2003","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ijcard.2016.09.081_bb0340","first-page":"49","article-title":"Familial hypercholesterolaemia","volume":"25","author":"Marais","year":"2004","journal-title":"Clin. Biochem. Rev."},{"issue":"9753","key":"10.1016\/j.ijcard.2016.09.081_bb0345","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ijcard.2016.09.081_bb0350","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jacc.2016.03.519","volume":"68","author":"Lloyd-Jones","year":"2016","journal-title":"J Am Coll Cardiol."},{"issue":"25","key":"10.1016\/j.ijcard.2016.09.081_bb0355","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","volume":"106","year":"2002","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.ijcard.2016.09.081_bb0360","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1001\/jama.2012.366","article-title":"Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis","volume":"307","author":"Boekholdt","year":"2012","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.ijcard.2016.09.081_bb0365","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.jacc.2008.10.024","article-title":"Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk","volume":"53","author":"Robinson","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"issue":"6","key":"10.1016\/j.ijcard.2016.09.081_bb0370","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1111\/j.1476-5381.2012.02081.x","article-title":"Cardiovascular disease risk reduction by raising HDL cholesterol\u2014current therapies and future opportunities","volume":"167","author":"Mahdy Ali","year":"2012","journal-title":"Br. J. Pharmacol."},{"issue":"13","key":"10.1016\/j.ijcard.2016.09.081_bb0375","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJMoa064278","article-title":"HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events","volume":"357","author":"Barter","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.ijcard.2016.09.081_bb0380","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1172\/JCI114558","article-title":"Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit","volume":"85","author":"Badimon","year":"1990","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.ijcard.2016.09.081_bb0385","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1161\/CIRCRESAHA.114.300760","article-title":"High-density lipoprotein and atherosclerosis regression: evidence from preclinical and clinical studies","volume":"114","author":"Feig","year":"2014","journal-title":"Circ. Res."},{"issue":"25","key":"10.1016\/j.ijcard.2016.09.081_bb0390","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1016\/j.jacc.2010.01.053","article-title":"Low high-density lipoprotein cholesterol and chronic disease risk marker or causal?","volume":"55","author":"Robinson","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"issue":"9943","key":"10.1016\/j.ijcard.2016.09.081_bb0395","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S0140-6736(14)61177-6","article-title":"Triglycerides and cardiovascular disease","volume":"384","author":"Nordestgaard","year":"2014","journal-title":"Lancet"},{"issue":"9726","key":"10.1016\/j.ijcard.2016.09.081_bb0400","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1016\/S0140-6736(10)60545-4","article-title":"Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies","volume":"375","author":"Sarwar","year":"2010","journal-title":"Lancet"},{"issue":"9729","key":"10.1016\/j.ijcard.2016.09.081_bb0405","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1016\/S0140-6736(10)60656-3","article-title":"Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis","volume":"375","author":"Jun","year":"2010","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ijcard.2016.09.081_bb0410","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/FJC.0b013e318202709f","article-title":"Fibrates effect on cardiovascular risk is greater in patients with high triglyceride levels or atherogenic dyslipidemia profile: a systematic review and meta-analysis","volume":"57","author":"Bruckert","year":"2011","journal-title":"J. Cardiovasc. Pharmacol."},{"issue":"4","key":"10.1016\/j.ijcard.2016.09.081_bb0415","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/j.1582-4934.2001.tb00172.x","article-title":"Statins: mechanism of action and effects","volume":"5","author":"Stancu","year":"2001","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.ijcard.2016.09.081_bb0420","doi-asserted-by":"crossref","first-page":"69","DOI":"10.17987\/icfj.v6i0.160","article-title":"Intensive lipid lowering therapy among patients with coronary artery disease: a Middle Eastern tertiary care center experience","volume":"6","author":"Garabedian","year":"2016","journal-title":"Int. Cardiovasc. Forum J."},{"issue":"10","key":"10.1016\/j.ijcard.2016.09.081_bb0425","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1177\/0003319713512414","article-title":"Centralized pan-Middle East Survey on the undertreatment of hypercholesterolemia: results from the CEPHEUS study in Arabian Gulf countries","volume":"65","author":"Arafah","year":"2014","journal-title":"Angiology"},{"issue":"12","key":"10.1016\/j.ijcard.2016.09.081_bb0430","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1185\/03007995.2014.965774","article-title":"Therapeutic lipid target achievements among high and highest risk patients: results from the CEPHEUS study in the Arabian Gulf","volume":"30","author":"Al-Rasadi","year":"2014","journal-title":"Curr. Med. Res. Opin."},{"issue":"3","key":"10.1016\/j.ijcard.2016.09.081_bb0435","doi-asserted-by":"crossref","first-page":"140","DOI":"10.17987\/icfj.v1i3.39","article-title":"Trends in coronary heart disease mortality and statin utilization in two European areas with different population risk levels: Stockholm and Sicily","volume":"1","author":"Vancheri","year":"2014","journal-title":"Int. Cardiovasc. Forum J."},{"issue":"6","key":"10.1016\/j.ijcard.2016.09.081_bb0440","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1177\/2047487315569401","article-title":"EUROASPIRE IV: a European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries","volume":"23","author":"Kotseva","year":"2016","journal-title":"Eur. J. Prev. Cardiol."},{"issue":"5","key":"10.1016\/j.ijcard.2016.09.081_bb0445","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.amjcard.2006.10.022","article-title":"Efficacy and safety of rosuvastatin 40mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study)","volume":"99","author":"Ballantyne","year":"2007","journal-title":"Am. J. Cardiol."},{"issue":"16","key":"10.1016\/j.ijcard.2016.09.081_bb0450","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/j.jacc.2008.03.003","article-title":"Lipid-altering efficacy and safety of ezetimibe\/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia","volume":"51","author":"Guyton","year":"2008","journal-title":"J. Am. Coll. Cardiol."},{"issue":"23","key":"10.1016\/j.ijcard.2016.09.081_bb0455","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1016\/j.jacc.2014.03.018","article-title":"Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab","volume":"63","author":"Koren","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"issue":"1","key":"10.1016\/j.ijcard.2016.09.081_bb0460","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ijcard.2014.06.049","article-title":"Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24week, double-blind, randomized Phase 3 trial","volume":"176","author":"Roth","year":"2014","journal-title":"Int. J. Cardiol."},{"issue":"8","key":"10.1016\/j.ijcard.2016.09.081_bb0465","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1210\/jc.2015-1520","article-title":"Alirocumab as add-on to atorvastatin versus other lipid treatment strategies: ODYSSEY OPTIONS I Randomized Trial","volume":"100","author":"Bays","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"16","key":"10.1016\/j.ijcard.2016.09.081_bb0470","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2016.09.081_bb0475","author":"European Medicines Agency"},{"key":"10.1016\/j.ijcard.2016.09.081_bb0480","author":"European Medicines Agency"},{"issue":"18","key":"10.1016\/j.ijcard.2016.09.081_bb0485","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1001\/jama.2014.4030","article-title":"Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial","volume":"311","author":"Robinson","year":"2014","journal-title":"JAMA"},{"issue":"9965","key":"10.1016\/j.ijcard.2016.09.081_bb0490","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(14)61399-4","article-title":"PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.ijcard.2016.09.081_bb0495","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1316222","article-title":"A 52-week placebo-controlled trial of evolocumab in hyperlipidemia","volume":"370","author":"Blom","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.ijcard.2016.09.081_bb0500","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1001\/archinte.163.5.553","article-title":"Risk for myopathy with statin therapy in high-risk patients","volume":"163","author":"Ballantyne","year":"2003","journal-title":"Arch. Intern. Med."},{"issue":"25","key":"10.1016\/j.ijcard.2016.09.081_bb0505","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.ijcard.2016.09.081_bb0510","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jacc.2015.10.077","article-title":"Reduction in total cardiovascular events with ezetimibe\/simvastatin post-acute coronary syndrome: The IMPROVE-IT trial","volume":"67","author":"Murphy","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2016.09.081_bb0515","author":"European Medicines Agency"},{"key":"10.1016\/j.ijcard.2016.09.081_bb0520","author":"European Medicines Agency"},{"key":"10.1016\/j.ijcard.2016.09.081_bb0525","author":"Food and Drug Administration Center for Drug Evaluation and Research"},{"issue":"4","key":"10.1016\/j.ijcard.2016.09.081_bb0530","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1161\/CIRCGENETICS.114.000952","article-title":"Effect of bile acid sequestrants on the risk of cardiovascular events: a mendelian randomization analysis","volume":"8","author":"Ross","year":"2015","journal-title":"Circ. Cardiovasc. Genet."},{"issue":"3","key":"10.1016\/j.ijcard.2016.09.081_bb0535","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1001\/jama.1984.03340270043026","article-title":"The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering","volume":"251","author":"Lipid Research Clinics Program","year":"1984","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.ijcard.2016.09.081_bb0540","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.atherosclerosis.2006.11.037","article-title":"Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study)","volume":"192","author":"McKenney","year":"2007","journal-title":"Atherosclerosis"},{"issue":"17","key":"10.1016\/j.ijcard.2016.09.081_bb0545","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/eurheartj\/eht055","article-title":"HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin\/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment","volume":"34","year":"2013","journal-title":"Eur. Heart J."},{"issue":"17","key":"10.1016\/j.ijcard.2016.09.081_bb0550","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1056\/NEJMp1508120","article-title":"Reducing LDL with PCSK9 inhibitors\u2014the clinical benefit of lipid drugs","volume":"373","author":"Everett","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2016.09.081_bb0555","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1186\/s12916-015-0503-4","article-title":"PCSK9 inhibition: the way forward in the treatment of dyslipidemia","volume":"13","author":"Stoekenbroek","year":"2015","journal-title":"BMC Med."},{"issue":"12","key":"10.1016\/j.ijcard.2016.09.081_bb0560","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/j.cjca.2013.09.023","article-title":"Diagnosis, prevention and management of statin adverse effects and intolerance: Canadian Consensus Working Group update","volume":"29","author":"Mancini","year":"2016","journal-title":"Can. J. Cardiol."},{"key":"10.1016\/j.ijcard.2016.09.081_bb0565","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s12916-015-0358-8","article-title":"Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials","volume":"13","author":"Zhang","year":"2015","journal-title":"BMC Med."},{"issue":"16","key":"10.1016\/j.ijcard.2016.09.081_bb0570","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","article-title":"Efficacy and safety of evolocumab in reducing lipids and cardiovascular events","volume":"372","author":"Sabatine","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.ijcard.2016.09.081_bb0575","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1093\/ajcn\/84.2.289","article-title":"Global nutrition dynamics: the world is shifting rapidly toward a diet linked with noncommunicable diseases","volume":"84","author":"Popkin","year":"2006","journal-title":"Am. J. Clin. Nutr."},{"key":"10.1016\/j.ijcard.2016.09.081_bb0580","author":"Food and Agriculture Organization of the United Nations Statistics Division (FAOSTAT)"},{"issue":"3\u20134","key":"10.1016\/j.ijcard.2016.09.081_bb0585","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1159\/000321527","article-title":"Nutrition transition and cardiovascular disease risk factors in Middle East and North Africa countries: reviewing the evidence","volume":"57","author":"Mehio Sibai","year":"2010","journal-title":"Ann. Nutr. Metab."},{"key":"10.1016\/j.ijcard.2016.09.081_bb0590","doi-asserted-by":"crossref","first-page":"27486","DOI":"10.3402\/fnr.v59.27486","article-title":"Association between dietary pattern and risk of cardiovascular disease among adults in the Middle East and North Africa region: a systematic review","volume":"59","author":"Aljefree","year":"2015","journal-title":"Food Nutr. Res."},{"issue":"8","key":"10.1016\/j.ijcard.2016.09.081_bb0595","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1093\/jn\/138.8.1469","article-title":"Food intake patterns may explain the high prevalence of cardiovascular risk factors among Iranian women","volume":"138","author":"Esmaillzadeh","year":"2008","journal-title":"J. Nutr."},{"issue":"17","key":"10.1016\/j.ijcard.2016.09.081_bb0600","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1161\/CIRCULATIONAHA.106.676379","article-title":"International Day for the Evaluation of Abdominal Obesity (IDEA): a study of waist circumference, cardiovascular disease, and diabetes mellitus in 168,000 primary care patients in 63 countries","volume":"116","author":"Balkau","year":"2007","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.ijcard.2016.09.081_bb0605","first-page":"243","article-title":"Appropriate waist circumference cut-off points among Iranian adults: the first report of the Iranian National Committee of Obesity","volume":"13","author":"Azizi","year":"2010","journal-title":"Arch. Iran. Med."},{"issue":"5","key":"10.1016\/j.ijcard.2016.09.081_bb0610","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1002\/dmrr.2642","article-title":"Sex and ethnic-origin specific BMI cut points improve prediction of 40-year mortality: the Israel GOH study","volume":"31","author":"Dankner","year":"2015","journal-title":"Diabetes Metab. Res. Rev."},{"issue":"4","key":"10.1016\/j.ijcard.2016.09.081_bb0615","doi-asserted-by":"crossref","first-page":"304","DOI":"10.3132\/dvdr.2008.044","article-title":"Optimal cut-points for body mass index, waist circumference and waist-to-hip ratio using the Framingham coronary heart disease risk score in an Arab population of the Middle East","volume":"5","author":"Al-Lawati","year":"2008","journal-title":"Diab. Vasc. Dis. Res."},{"issue":"2","key":"10.1016\/j.ijcard.2016.09.081_bb0620","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1001\/jama.2013.284692","article-title":"Smoking prevalence and cigarette consumption in 187 countries, 1980\u20132012","volume":"311","author":"Ng","year":"2014","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.ijcard.2016.09.081_bb0625","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.amjcard.2004.10.012","article-title":"Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial)","volume":"95","author":"Grundy","year":"2005","journal-title":"Am. J. Cardiol."},{"issue":"3","key":"10.1016\/j.ijcard.2016.09.081_bb0630","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2337\/dc08-1543","article-title":"Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study","volume":"32","author":"Scott","year":"2009","journal-title":"Diabetes Care"},{"issue":"6a","key":"10.1016\/j.ijcard.2016.09.081_bb0635","doi-asserted-by":"crossref","first-page":"3c","DOI":"10.1016\/j.amjcard.2006.11.016","article-title":"Safety considerations with fibrate therapy","volume":"99","author":"Davidson","year":"2007","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ijcard.2016.09.081_bb0640","author":"US National Institutes of Health. Clinicaltrials.gov"},{"key":"10.1016\/j.ijcard.2016.09.081_bb0645","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.plipres.2014.07.002","article-title":"Recent advances in pharmacotherapy for hypertriglyceridemia","volume":"56","author":"Sahebkar","year":"2014","journal-title":"Prog. Lipid Res."},{"key":"10.1016\/j.ijcard.2016.09.081_bb0650","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12944-016-0197-4","article-title":"Effect of alirocumab on specific lipoprotein non-high-density lipoprotein cholesterol and subfractions as measured by the vertical auto profile method: analysis of 3 randomized trials versus placebo","volume":"15","author":"Toth","year":"2016","journal-title":"Lipids Health Dis."},{"issue":"33","key":"10.1016\/j.ijcard.2016.09.081_bb0655","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1093\/eurheartj\/ehu085","article-title":"Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials","volume":"35","author":"Stein","year":"2014","journal-title":"Eur. Heart J."},{"issue":"12","key":"10.1016\/j.ijcard.2016.09.081_bb0660","doi-asserted-by":"crossref","first-page":"A1373","DOI":"10.1016\/S0735-1097(14)61373-5","article-title":"Effects of alirocumab, a fully human monoclonal antibody to proprotein convertase subtilisin\/kexin type 9, on lipoprotein particle concentrations determined by nuclear magnetic resonance: substudy of a randomized double-blind Phase II clinical trial","volume":"63","author":"Koren","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"issue":"13","key":"10.1016\/j.ijcard.2016.09.081_bb0665","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.jacc.2014.01.006","article-title":"Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials","volume":"63","author":"Raal","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"issue":"5","key":"10.1016\/j.ijcard.2016.09.081_bb0670","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.amjcard.2014.05.060","article-title":"Effect of alirocumab, a monoclonal proprotein convertase subtilisin\/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150mg every two weeks dosing from phase 2 trials)","volume":"114","author":"Gaudet","year":"2014","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ijcard.2016.09.081_bb0675","series-title":"IDF Diabetes Atlas","author":"International Diabetes Federation","year":"2015"},{"issue":"3\u20134","key":"10.1016\/j.ijcard.2016.09.081_bb0680","doi-asserted-by":"crossref","first-page":"c120","DOI":"10.1159\/000345149","article-title":"Chronic kidney disease in the Arab world: a call for action","volume":"121","author":"Farag","year":"2012","journal-title":"Nephron Clin. Pract."},{"key":"10.1016\/j.ijcard.2016.09.081_bb0685","author":"World Health Organization"},{"issue":"3","key":"10.1016\/j.ijcard.2016.09.081_bb0690","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/ncpendmet1066","article-title":"Dyslipidemia in type 2 diabetes mellitus","volume":"5","author":"Mooradian","year":"2009","journal-title":"Nat. Clin. Pract. Endocrinol. Metab."},{"issue":"3","key":"10.1016\/j.ijcard.2016.09.081_bb0695","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/01.crd.0000188034.76283.5e","article-title":"Management of dyslipidemia in diabetes","volume":"14","author":"Solano","year":"2006","journal-title":"Cardiol. Rev."},{"issue":"8","key":"10.1016\/j.ijcard.2016.09.081_bb0700","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0022186","article-title":"Quality of type 2 diabetes management in the states of the Co-operation Council for the Arab States of the Gulf: a systematic review","volume":"6","author":"Alhyas","year":"2011","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.ijcard.2016.09.081_bb0705","doi-asserted-by":"crossref","first-page":"805","DOI":"10.2337\/dc07-1117","article-title":"Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study","volume":"31","author":"Ilanne-Parikka","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ijcard.2016.09.081_bb0710","first-page":"CG181","article-title":"Cardiovascular disease: risk assessment and reduction, including lipid modification","author":"National Institute for Health and Care Excellence","year":"2014","journal-title":"Clin. Guidel."},{"issue":"17","key":"10.1016\/j.ijcard.2016.09.081_bb0715","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"ACCORD Study Group","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"8 Suppl.","key":"10.1016\/j.ijcard.2016.09.081_bb0720","first-page":"1S9","article-title":"Review of studies on the effect of bile acid sequestrants in patients with type 2 diabetes mellitus","author":"Levy","year":"2010","journal-title":"Metab. Syndr. Relat. Disord."},{"issue":"5","key":"10.1016\/j.ijcard.2016.09.081_bb0725","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/j.1463-1326.2009.01181.x","article-title":"Colesevelam lowers glucose and lipid levels in type 2 diabetes: the clinical evidence","volume":"12","author":"Fonseca","year":"2010","journal-title":"Diabetes Obes. Metab."},{"issue":"5","key":"10.1016\/j.ijcard.2016.09.081_bb0730","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S2213-8587(16)00003-6","article-title":"Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data","volume":"4","author":"Sattar","year":"2016","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.ijcard.2016.09.081_bb0735","series-title":"Poster presented at: European Association for the Study of Diabetes","article-title":"Efficacy and safety of alirocumab in individuals with diabetes: analyses from the ODYSSEY LONG TERM study","author":"Colhoun","year":"2015"},{"issue":"1","key":"10.1016\/j.ijcard.2016.09.081_bb0740","doi-asserted-by":"crossref","first-page":"84","DOI":"10.4158\/EP151126.CS","article-title":"Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2016 executive summary","volume":"22","author":"Garber","year":"2016","journal-title":"Endocr. Pract."},{"issue":"Suppl. 1","key":"10.1016\/j.ijcard.2016.09.081_bb0745","doi-asserted-by":"crossref","first-page":"S60","DOI":"10.2337\/dc16-S011","article-title":"Cardiovascular disease and risk management","volume":"39","author":"American Diabetes Association","year":"2016","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.ijcard.2016.09.081_bb0750","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.amjcard.2004.09.013","article-title":"Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project)","volume":"95","author":"Canner","year":"2005","journal-title":"Am. J. Cardiol."},{"issue":"6","key":"10.1016\/j.ijcard.2016.09.081_bb0755","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1007\/s00125-003-1116-6","article-title":"Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes","volume":"46","author":"Laing","year":"2003","journal-title":"Diabetologia"},{"issue":"12","key":"10.1016\/j.ijcard.2016.09.081_bb0760","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1038\/ki.2011.368","article-title":"The contribution of chronic kidney disease to the global burden of major noncommunicable diseases","volume":"80","author":"Couser","year":"2011","journal-title":"Kidney Int."},{"issue":"9889","key":"10.1016\/j.ijcard.2016.09.081_bb0765","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0140-6736(13)60595-4","article-title":"Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention","volume":"382","author":"Gansevoort","year":"2013","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.ijcard.2016.09.081_bb0770","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1046\/j.1523-1755.2002.00600.x","article-title":"The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia","volume":"62","author":"Himmelfarb","year":"2002","journal-title":"Kidney Int."},{"key":"10.1016\/j.ijcard.2016.09.081_bb0775","doi-asserted-by":"crossref","DOI":"10.1007\/s40620-015-0260-7","article-title":"Abdominal aortic calcification in patients with CKD","author":"Peeters","year":"2016","journal-title":"J. Nephrol."},{"issue":"3","key":"10.1016\/j.ijcard.2016.09.081_bb0780","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1007\/s10157-015-1169-0","article-title":"Impact of non-invasive cardiovascular screening programs as a predictor of cardiovascular events among asymptomatic chronic kidney disease patients","volume":"20","author":"Sawai","year":"2016","journal-title":"Clin. Exp. Nephrol."},{"issue":"2","key":"10.1016\/j.ijcard.2016.09.081_bb0785","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1681\/ASN.2014020173","article-title":"Subclinical atherosclerosis measures for cardiovascular prediction in CKD","volume":"26","author":"Matsushita","year":"2015","journal-title":"J. Am. Soc. Nephrol."},{"issue":"5","key":"10.1016\/j.ijcard.2016.09.081_bb0790","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1053\/j.ajkd.2008.04.012","article-title":"Prevalence and associations of coronary artery calcification in patients with stages 3 to 5 CKD without cardiovascular disease","volume":"52","author":"Garland","year":"2008","journal-title":"Am. J. Kidney Dis."},{"issue":"1","key":"10.1016\/j.ijcard.2016.09.081_bb0795","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1159\/000350580","article-title":"Coronary artery calcification and outcomes in diabetic patients with and without chronic kidney disease","volume":"36","author":"Russo","year":"2013","journal-title":"Blood Purif."},{"key":"10.1016\/j.ijcard.2016.09.081_bb0800","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1471-2369-14-10","article-title":"Calcification of coronary arteries and abdominal aorta in relation to traditional and novel risk factors of atherosclerosis in hemodialysis patients","volume":"14","author":"Pencak","year":"2013","journal-title":"BMC Nephrol."},{"issue":"Suppl. 1","key":"10.1016\/j.ijcard.2016.09.081_bb0805","first-page":"S85","article-title":"Kidney health in the Middle East","volume":"74","author":"Shaheen","year":"2010","journal-title":"Clin. Nephrol."},{"issue":"6","key":"10.1016\/j.ijcard.2016.09.081_bb0810","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1258\/shorts.2012.011150","article-title":"Epidemiology of end-stage renal disease in the countries of the Gulf Cooperation Council: a systematic review","volume":"3","author":"Hassanien","year":"2012","journal-title":"JRSM Short Rep."},{"issue":"4","key":"10.1016\/j.ijcard.2016.09.081_bb0815","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/kisup.2013.64","article-title":"Hypertension and chronic kidney disease in Turkey","volume":"3","author":"Sengul","year":"2013","journal-title":"Kidney Int. Suppl."},{"issue":"1","key":"10.1016\/j.ijcard.2016.09.081_bb0820","first-page":"99","article-title":"The epidemiology of adult chronic kidney disease in a population-based study in Iran: prevalence and associated risk factors","volume":"22","author":"Safarinejad","year":"2009","journal-title":"J. Nephrol."},{"issue":"2","key":"10.1016\/j.ijcard.2016.09.081_bb0825","first-page":"109","article-title":"Prevalence of chronic kidney disease and its contributing risk factors in southern Iran: a cross-sectional adult population-based study","volume":"8","author":"Khajehdehi","year":"2014","journal-title":"Iran. J. Kidney Dis."},{"issue":"9","key":"10.1016\/j.ijcard.2016.09.081_bb0830","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0045304","article-title":"Incidence of chronic kidney disease and its risk factors, results of over 10year follow up in an Iranian cohort","volume":"7","author":"Tohidi","year":"2012","journal-title":"PLoS One"},{"issue":"2 Suppl. 2","key":"10.1016\/j.ijcard.2016.09.081_bb0835","first-page":"S2-2-4","article-title":"Incidence, prevalence, and treatment of end-stage renal disease in the Middle East","volume":"16","author":"Abboud","year":"2006","journal-title":"Ethn. Dis."},{"issue":"6","key":"10.1016\/j.ijcard.2016.09.081_bb0840","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1681\/ASN.2012080870","article-title":"Association between LDL-C and risk of myocardial infarction in CKD","volume":"24","author":"Tonelli","year":"2013","journal-title":"J. Am. Soc. Nephrol."},{"issue":"9784","key":"10.1016\/j.ijcard.2016.09.081_bb0845","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet"},{"issue":"3 Suppl.","key":"10.1016\/j.ijcard.2016.09.081_bb0850","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/j.jacl.2014.02.010","article-title":"The National Lipid Association's Safety Task Force. A clinician's guide to statin drug-drug interactions","volume":"8","author":"Kellick","year":"2014","journal-title":"J. Clin. Lipidol."},{"issue":"2","key":"10.1016\/j.ijcard.2016.09.081_bb0855","doi-asserted-by":"crossref","first-page":"139","DOI":"10.18553\/jmcp.2013.19.2.139","article-title":"Management of familial hypercholesterolemia: a review of the recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia","volume":"19","author":"Robinson","year":"2013","journal-title":"J. Manag. Care Pharm."},{"issue":"45","key":"10.1016\/j.ijcard.2016.09.081_bb0860","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","article-title":"Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society","volume":"34","author":"Nordestgaard","year":"2013","journal-title":"Eur. Heart J."},{"issue":"12","key":"10.1016\/j.ijcard.2016.09.081_bb0865","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1016\/j.cjca.2014.09.028","article-title":"Canadian Cardiovascular Society position statement on familial hypercholesterolemia","volume":"30","author":"Genest","year":"2014","journal-title":"Can. J. Cardiol."},{"issue":"9","key":"10.1016\/j.ijcard.2016.09.081_bb0870","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1093\/eurheartj\/ehu058","article-title":"Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome","volume":"36","author":"Sjouke","year":"2015","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2016.09.081_bb0875","series-title":"Report of a second WHO consultation","article-title":"Familial hypercholesterolaemia (FH)","author":"World Health Organization","year":"1998"},{"issue":"1","key":"10.1016\/j.ijcard.2016.09.081_bb0880","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1055\/s-2004-822987","article-title":"Advanced method for the identification of patients with inherited hypercholesterolemia","volume":"4","author":"Defesche","year":"2004","journal-title":"Semin. Vasc. Med."},{"issue":"12","key":"10.1016\/j.ijcard.2016.09.081_bb0885","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1136\/jmg.2006.038356","article-title":"Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk","volume":"43","author":"Humphries","year":"2006","journal-title":"J. Med. Genet."},{"issue":"2","key":"10.1016\/j.ijcard.2016.09.081_bb0890","doi-asserted-by":"crossref","first-page":"85","DOI":"10.5001\/omj.2014.22","article-title":"Criteria for diagnosis of familial hypercholesterolemia: a comprehensive analysis of the different guidelines, appraising their suitability in the Omani Arab population","volume":"29","author":"Al-Rasadi","year":"2014","journal-title":"Oman Med. J."},{"key":"10.1016\/j.ijcard.2016.09.081_bb0895","author":"European Medicines Agency"},{"key":"10.1016\/j.ijcard.2016.09.081_bb0900","author":"Food and Drug Administration"},{"issue":"9860","key":"10.1016\/j.ijcard.2016.09.081_bb0905","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(12)61731-0","article-title":"Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study","volume":"381","author":"Cuchel","year":"2013","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ijcard.2016.09.081_bb0910","first-page":"119","article-title":"Mipomersen (kynamro): a novel antisense oligonucleotide inhibitor for the management of homozygous familial hypercholesterolemia","volume":"39","author":"Wong","year":"2014"},{"issue":"9719","key":"10.1016\/j.ijcard.2016.09.081_bb0915","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(10)60284-X","article-title":"Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial","volume":"375","author":"Raal","year":"2010","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.ijcard.2016.09.081_bb0920","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0049006","article-title":"Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy","volume":"7","author":"McGowan","year":"2012","journal-title":"PLoS One"},{"issue":"19","key":"10.1016\/j.ijcard.2016.09.081_bb0925","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1161\/CIRCULATIONAHA.113.004678","article-title":"Effect of the proprotein convertase subtilisin\/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia","volume":"128","author":"Stein","year":"2013","journal-title":"Circulation"},{"issue":"9965","key":"10.1016\/j.ijcard.2016.09.081_bb0930","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(14)61374-X","article-title":"Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.ijcard.2016.09.081_bb0935","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1002\/art.24092","article-title":"Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies","volume":"59","author":"Avi\u00f1a-Zubieta","year":"2008","journal-title":"Arthritis Rheum."},{"issue":"10 Suppl. 1","key":"10.1016\/j.ijcard.2016.09.081_bb0940","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/j.amjmed.2008.06.011","article-title":"Cardiovascular morbidity and mortality in rheumatoid arthritis","volume":"121","author":"Gabriel","year":"2008","journal-title":"Am. J. Med."},{"issue":"6","key":"10.1016\/j.ijcard.2016.09.081_bb0945","doi-asserted-by":"crossref","first-page":"720.e1","DOI":"10.1016\/j.ajog.2015.12.038","article-title":"Safety and pharmacokinetics of pravastatin used for the prevention of preeclampsia in high-risk pregnant women: a pilot randomized controlled trial","volume":"214","author":"Costantine","year":"2016","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"1","key":"10.1016\/j.ijcard.2016.09.081_bb0950","first-page":"299","article-title":"Dilemmas in treatment of women with familial hypercholesterolaemia during pregnancy","volume":"68","author":"Kusters","year":"2010","journal-title":"Neth. J. Med."},{"issue":"2","key":"10.1016\/j.ijcard.2016.09.081_bb0955","doi-asserted-by":"crossref","first-page":"138.e","DOI":"10.1016\/j.ajog.2008.10.001","article-title":"Duration of lactation and incidence of myocardial infarction in middle to late adulthood","volume":"200","author":"Stuebe","year":"2009","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"5","key":"10.1016\/j.ijcard.2016.09.081_bb0960","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1097\/01.AOG.0000346884.67796.ca","article-title":"Duration of lactation and risk factors for maternal cardiovascular disease","volume":"113","author":"Schwarz","year":"2009","journal-title":"Obstet. Gynecol."},{"issue":"17","key":"10.1016\/j.ijcard.2016.09.081_bb0965","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.2174\/1381612811319170023","article-title":"Mitochondrial triglyceride transfer protein inhibition: new achievements in the treatment of dyslipidemias","volume":"19","author":"Kostapanos","year":"2013","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.ijcard.2016.09.081_bb0970","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2147\/VHRM.S36641","article-title":"Inhibition of hepatic microsomal triglyceride transfer protein - a novel therapeutic option for treatment of homozygous familial hypercholesterolemia","volume":"10","author":"Vuorio","year":"2014","journal-title":"Vasc. Health Risk Manag."}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527316325074?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527316325074?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,9]],"date-time":"2022-07-09T14:44:52Z","timestamp":1657377892000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527316325074"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":194,"alternative-id":["S0167527316325074"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2016.09.081","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Consensus clinical recommendations for the management of plasma lipid disorders in the Middle East","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2016.09.081","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Author(s). Published by Elsevier Ireland Ltd.","name":"copyright","label":"Copyright"}]}}